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Studies o f Medical Costs

Previous Studies
In this section I will briefly review previous studies that estimated life time medical costs of smoking. Leu and Schaub (1983, 1985) estimated that total expected lifetime medical care expenditures beginning at age 35 for Swiss males who do not smoke will be higher than for smokers. Among Swiss males, the contribution of longer life expectancy to medi cal care expenditures for neversmokers outweighed the higher average annual expenditures for smokers.
In the first version of their study (1983) , Leu and Schaub assumed that medical care utilization is related to smoking in the same way that mortality is related to smoking. Thus, it was estimated that the average male smoker has 8 percent more physician visits and 10 percent more hospital days per year than the neversmoker. In a revised version (1985) , Leu and Schaub analyzed the demand for medical care in Switzerland using an econometric model and concluded that smokers have somewhat fewer physician visits and slightly more hospital days than neversmokers. The conclusion reached by Leu and Schaub in their first article, that smoking does not increase lifetime medical expenditures, was reaffirmed.
In the United States, excess medical care utilization by smokers is much higher than that reported by Leu and Schaub. In the National Health Interview Survey (NHIS) Rice et al. (1986) found that the average male smoker (17 years of age and over) had 19 percent more physician visits and 63 percent more hospital days per year than neversmokers. This is 2.4 times the excess physician visits and 6.3 times the excess hos pital days reported by Leu and Schaub for Swiss males. The higher an nual excess medical care o f smokers revealed in the U.S. data cumulated over the years a smoker is alive might more than offset the impact of a longer life span on medical care use of neversmokers. Lippiatt (1990) also reported that smoking lowers lifetime medical costs. This was derived by deducting from expected lifetime medical ex penditures required to treat a smoker for certain smoking-related dis eases the additional medical costs incurred during the longer life of a nonsmoker. Although methodologically sound, lifetime medical costs of smoking were underestimated because the data employed both underes timate expenditures for the smoker's smoking-related diseases and over estimate medical costs during the longer life o f the nonsmoker.
For lifetime costs o f smoking-related diseases Lippiatt used the figures of Oster et al. (1984a,b) for the expected lifetime costs of lung cancer, coronary heart disease, and emphysema. Although these three condi tions are important smoking-related diseases, in addition, cigarette smoking is a major agent for chronic bronchitis, cerebrovascular disease, peripheral artery occlusive disease, and cancers of the oral cavity, larynx, and esophagus as well as causing bladder cancer. Smoking also increases the risk of pneumonia and influenza, abdominal aortic aneurysm, and gastric and duodenal ulcers; it is a contributing factor in cancers of the pancreas and kidney; and it is associated with cancers of the stomach and uterine cervix (U.S. Department of Health and Human Services 1989, 1990) . Lung cancer, coronary heart disease, and emphysema ac count for less than half of the total short-term hospital days required for all diseases linked to cigarette smoking (Graham 1988) . Just the addi tional diseases for which smoking is a major cause require hospital days equal to 60 percent of the total for the three conditions studied by Os ter. By limiting the calculation to costs of lung cancer, coronary heart disease, and emphysema, Lippiatt omitted substantial morbidity, mor tality, and health care utilization and severely underestimated lifetime medical costs of smoking.
In order to take into account the longer life and medical care expen ditures of nonsmokers during these extra years, Lippiatt adjusted the es timates by Oster et al. of lifetime costs of smoking-related diseases. This was done by subtracting estimated average annual per capita medical ex penditures of nonsmokers over age 65 for each year of difference in life expectancy between smokers and nonsmokers. Average expenditures for nonsmokers were derived from per capita expenditures for the total pop ulation over age 65 (smokers and nonsmokers), the proportion of smok ers and nonsmokers in this population, and the difference in average annual medical expenditures between smokers and nonsmokers reported by Leu and Schaub (1983) . Because Leu and Schaub severely underesti mated the difference in annual medical care use and expenditures be tween smokers and nonsmokers in the United States, Lippiatt's estimate of a nonsmoker's annual medical expenditures is overstated.
By excluding expenditures for diseases known to be caused by smoking and understating medical care utilization and expenditure differences between smokers and nonsmokers, Lippiatt underestimated lifetime medical costs o f smoking. Because Lippiatt finds the tradeoff between medical expenditures and life expectancy to be only $280 per year of ex tra life for nonsmokers (in 1986 dollars), we expect more accurate esti mates of the costs of smoking-related diseases and the annual medical expenditures o f nonsmokers would produce lifetime medical costs higher for smokers than nonsmokers. Manning et al. (1989) examined lifetime medical care costs of smok ing from a somewhat different perspective, but found a positive rela tionship. Their best estimate is that medical ca e costs of smoking were $.26 per pack o f cigarettes smoked in 1986 dollars discounted at 5 percent.
Overview o f the Study
In our analysis we use a life-cycle model to verify the findings of Man ning et al. (1989) that in the United States smokers have higher lifetime medical expenditures. We also expand upon their analysis to examine the timing of expenditures over the life cycle, population as well as indi vidual expenditures, and sources of payment for medical care. Data em ployed are for the U.S. population and include medical care use and mortality for all diagnoses and causes of death, thus overcoming the limitations in the Leu and Schaub and Lippiatt studies.
Lifetime medical care expenditures are estimated for males and fe males in the United States who never smoked and for moderate and heavy smokers, including both current and former smokers. Moderate smokers reported smoking fewer than 25 cigarettes a day and heavy smokers smoked 25 or more per day. Analyzing eversmokers (that is, current and former smokers, hereafter called smokers) takes into account the number of years of smoking and patterns of quitting and recidivism existing in the population at the time of data collection. Thus, esti mated expected lifetime medical expenditures of a smoker reflect the average experience in the population of persons who take up smoking and include the impact on expenditures of decisions to quit smoking. In this study, comparison of lifetime expenditures of smokers and neversmokers allows us to assess the impact of becoming a smoker versus not becoming a smoker, but does not address the impact of quitting smok ing on medical care expenditures. Subsequent research is planned to an alyze quitting and lifetime medical expenditures.
From these estimates of lifetime medical expenditures we determine:
3. the relative importance to lifetime expenditures o f a smoker's higher medical care use and a neversmoker's longer life expectancy 4. the timing of medical expenditures during the life cycle and the phases during which expenditures of smokers exceed those of neversmokers and vice versa 5. the monetary burden smoking imposes on private sources of fund ing (for example, individuals and employers) and public sources (for example, the federal government's Medicare program) 6. the distribution of current medical care expenditures among the population of smokers and persons who never smoked 7. the ongoing bill for excess medical care required by the popula tion of smokers 8. the aggregate future excess expenditures of the current population of smokers
Other Economic Costs
There are other economic costs associated with smoking in addition to medical care expenditures. These include expenditures and payments re lated to sick leave, disability, group life insurance, pensions, and retire ment benefits (Manning et al. 1989; Warner 1987) . The impact of smoking on Social Security benefits is among the most important of these and is substantial. Shoven, Sundberg, and Bunker (1987) estimate that because of shorter life expectancy single male smokers earning the median wage receive almost $18,000 less in benefits than they contrib ute, whereas nonsmokers receive almost $3,400 more than they pay in (in 1985 dollars Pa, = probability of surviving through age interval t Pat = probability of dying during age interval t It is necessary to distinguish whether the individual survives or dies be cause much higher expenditures are incurred by decedents than sur vivors. Lifetime expenditures from age 17 are given by the sum of expected expenditures, Et , during each of the age intervals: t = ages 17-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85 and over Expenditures are discounted to obtain the present value of the stream of dollars occurring over time. It is assumed that all persons surviving to age 85 enjoy the average remaining lifetime calculated by the National Center for Health Statistics, or approximately five years for males and six years for females (National Center for Health Statistics 1990). This simplification is required by lack of data on life expectancy at age 85 for smokers and neversmokers resulting most likely in overestimates of ex penditures for smokers and underestimates of expenditures for never smokers at ages 85 and over. The impact on lifetime expenditures is negligible, however, because expected expenditures at age 85 and over are a small proportion of the total, especially among smokers.
Lifetime expenditures are estimated for males and females, and ac cording to amount smoked (never smoked, moderate, or heavy smoker). Age-and sex-specific rates of medical care use and mortality according to amount smoked are employed. Medical care expenditures included are for short-term inpatient hospital care, physicians' services (to hospi tal inpatients and ambulatory patients in doctors' offices, hospital clinics and emergency rooms, patients' homes, and by telephone), and nursinghome care. These medical services account for about three-fourths of to tal personal health care expenditures (Waldo et al. 1989) . The principal services omitted from the analysis because of lack of data on how utiliza tion relates to cigarette smoking are drugs and dental services.
Medical care utilization and expenditures are not evenly distributed throughout the life cycle. Variation of medical care use with age is easily accounted for by employing age-specific data. Equally important, dece dents require much more medical care and incur far greater expendi tures than survivors among both elderly and nonelderly populations. Decedents have higher expenditures relative to survivors, not only in the year of death, but also for several years prior to death. The disparity in expenditures of decedents versus survivors increases as the time of death approaches and may be more than six times greater in the year death oc curs (Lubitz and Prihoda 1984; Riley and Lubitz 1986; Roos, Montgom ery, and Roos 1987) . This phenomenon is an important aspect of lifetime medical expenditures and is included in the model.
D ollars
Expenditures in this analysis are in estimated 1990 dollars, with dollar magnitudes adjusted to 1990 according to increases in the medical care component of the consumer price index ( Social Security Bulletin 1991) .
D iscounting
Medical care use and expenditures are highly concentrated in the later years of life, especially in the several years before death. Because neversmokers live longer, their medical care expenditures are deferred to the future compared with those o f smokers. The very long time horizons in this analysis (65 years or more in some instances), and the different dis tributions of expenditures over time for smokers and neversmokers, re quire that lifetime expenditures be discounted in order not to overstate the amount for neversmokers compared with smokers. This analysis em ploys a relatively low, but reasonable, discount rate of 3 percent. Key re sults are also presented for a 5 percent discount rate to show the impact o f discounting. Total expected lifetime expenditures discounted at 3 percent are about one-third of nondiscounted expenditures.
C ausality o r A ssociation ?
How much o f the difference in medical care use and expenditures is due to smoking and how much to other factors that are not equally distrib uted among smokers and neversmokers? Smokers differ from never smokers in certain genetic, social, behavioral, and economic characteristics that may contribute to use of medical care. Positive correlations have been reported between smoking and drinking alcohol. The Behavioral Risk Factor Surveys, conducted from 1981 to 1983, found that more heavy smokers (more than one pack a day) had two or more drinks a day than neversmokers (Bradstock et al. 1985) . In a study at the Group Health Cooperative of Puget Sound, current smokers were more likely to be problem drinkers (Pearson et al. 1987) . Data from the National Health Interview Survey (NHIS) show that in 1985 smokers were more likely than neversmokers to drink heavily, not exercise actively, sleep six hours or less, and skip breakfast (Schoenbom and Benson 1988) . How ever, smokers, especially those who smoked fewer than 25 cigarettes daily, were less likely to be overweight and to snack daily.
If factors related to health status and smoking habits are not con trolled, the impact of smoking on health and medical expenditures may be overstated. There is evidence from several sources, however, that most of the observed difference between smokers and neversmokers in mortality, medical care use, and expenditures is the result of smoking and is not just correlated with it. Neversmokers, especially males, have higher income and more education than smokers, but the difference in medical care use cannot be attributed to health habits, practices, or life styles related to income and education because smokers use more medi cal care at all levels of income and education according to data from NHIS as computed by the Office of Analysis and Epidemiology. Matt son, Pollack, and Cullen (1987) estimated death rates for males in the United States in 1982 for smoking-related diseases and for all causes of death according to age and smoking status. Applying these estimates to the number of males in the civilian noninstinationalized population in 1985 by smoking status, it can be calculated that 74 percent of excess deaths among male smokers aged 35 to 84 was due to smoking-related diseases.
An interesting statistical construct, the nonsmoking smoker-type, has been employed to assess medical care expenditures due to smoking rather than just associated with smoking (Leu and Schaub 1983; Man ning et al. 1989 ). The nonsmoking smoker-type does not smoke but is like a smoker in other respects that distinguish smokers from neversmokers and contribute to morbidity, mortality, and medical care use. These include education, family income, race, health insurance cover age, and lifestyle attributes such as drinking habits, exercise, and seat belt use. Thus, the nonsmoking smoker-type experiences medical care use and mortality that lie between those o f the smoker and neversmoker.
Higher medical care use and higher mortality have opposite impacts on lifetime expenditures. Thus, the higher medical care use of the non smoking smoker-type will increase lifetime expenditures relative to neversmokers and decrease the excess lifetime expenditures associated with smoking. This will be partially offset, however, by the impact of the higher mortality rates of the nonsmoking smoker-type, which reduce life expectancy and thus lifetime expenditures relative to neversmokers and increase excess lifetime expenditures of smoking. Controlling for other differences between smokers and neversmokers besides smoking that af fect medical costs has a rather small impact on excess lifetime medical expenditures according to research reported by Manning et al. (1989) . Manning and his colleagues estimated lifetime medical costs per pack of cigarettes and found that excess lifetime costs of smokers compared with nonsmoking smoker-types were 87 percent of excess lifetime costs of smokers compared with neversmokers.
Although the preferred comparison for ascertaining medical care ex penditures due to smoking is between the smoker and nonsmoking smoker-type, we are only able to compare eversmokers and neversmok ers in our study. Nevertheless, because Manning et al. also used data from the NHIS, it is reasonable to conclude from their results that the findings we report would be only slightly different quantitatively and no different qualitatively if formulated in terms o f smokers versus non smoking smoker-types.
Lifetime Expenditures
M ortality
Smokers have higher death rates than neversmokers at all ages over 35 years (figure 1). The analysis begins at age 17 because data on medical care use and expenditures by smoking status are available beginning at this age. However, we lack data on mortality by smoking status for per sons aged 17 to 34 and it is assumed that no deaths occur until age 35. This assumption should have a negligible impart on our results because less than 4 percent of persons die before age 35 (National Center for Health Statistics 1990) and smoking should not be a major determinant of mortality between the ages of 17 and 35. Excluding deaths prior to age 35 has a slight impact on lifetime expenditures of both smokers and neversmokers and even less of an impact on the difference in their ex penditures. Death rates rise steadily with age, are higher for males than females, and higher for smokers than neversmokers in each sex.
Probabilities of survival are derived from the death rates. shown by sex and smoking status. Probabilities of survival are higher for females, but the same patterns are observed among smokers and neversmokers of both sexes. The benefit of lower death rates among neversmokers at all ages accumulates with age and creates a steadily widening gap in survival rates. For example, whereas 87 percent of male neversmokers and 73 percent of smokers survive to age 65, 34 percent of neversmokers survive to age 85 compared with only 16 percent of smokers. In terms of relative survival, out of male neversmokers and smokers alive at age 35, 18 percent more of the neversmokers survive to age 65, 48 percent more of the neversmokers survive to age 75, and more than twice as many of the neversmokers live to age 85. Among females, the probability of surviving is 8 percent higher for neversmokers at age 65, 20 percent higher at age 75, and 57 percent higher at age 85. Smoking exacts a much greater toll among males in terms of premature mortality. The disparity in mortality between male and female smokers reflects differences in cigarette smoke exposure (U.S. Department o f Health and Human Services 1980). The mean age o f onset o f regular smoking among successive cohorts o f men has been less than 20 years since before 1900. It has declined slowly over time to between 15 and 16 years for cohorts born between 1951 and I960. Among women born at the be ginning of the century, however, the mean age at onset was 35 years. Although this declined steadily, it was not until the 1951-1960 birth cohort, now 30 to 40 years of age, that it became nearly identical to that of men.
Exposure also depends on the likelihood o f quitting smoking. Among cigarette smokers, quit ratios (the proportion of eversmokers who are former smokers) have been increasing for both sexes at similar rates since 1965 (U.S. Department o f Health and Human Services 1990). Although higher for males than females, the gender difference is only a couple of percentage points when quit ratios are adjusted to ac count for use of other tobacco products besides cigarettes.
In addition to age at initiation and likelihood of quitting, smoke ex posure depends on various dimensions o f the style of smoking, includ ing type o f cigarette, depth of inhalation, and fraction of cigarette smoked. With each new generation, the surgeon general has concluded, men and women have become more similar in their smoking habits, and female exposure closer to that of men. In future years we can expect male and female mortality from smoking also to become more similar.
Mortality rates and probabilities of survival demonstrate that neversmokers live longer than smokers, and many more neversmokers reach those years of life characterized by high medical care expenditures. Dif ferences in death rates of smokers and neversmokers impact on medical care costs in two ways. On the one hand, there is a high cost associated with dying that is incurred earlier in the life span for smokers and has a present value diminished less by discounting, whereas those who live longer incur additional expenditures in later years that rise with age for both survivors and decedents (figure 2).
The disparity in medical care spending for older and younger per sons, coupled with the longer life expectancy o f neversmokers, raises the issue of whether neversmokers have higher lifetime medical expendi tures than smokers, with smoking holding down medical costs. In order to determine whether smokers or neversmokers have higher lifetime ex penditures, it is necessary to take into account differences not only in life expectancy, but also in medical care used and expenditures incurred during the years lived.
A ge-specific E xpenditures
In figure 2 we have age-specific medical expenditures for male smokers and neversmokers according to whether one survives to the end of the age interval or dies during it. For example, male smokers who survive to the end of the age span 45-54 incur an average o f $13,579 in medical care expenditures during these ten years, and male smokers who die be tween the ages o f 45 and 54 incur an average expenditure o f $33,201 per smoker. Neversmokers 45 to 54 years old who survive to age 55 re quire $9,175 per person, and neversmoker decedents aged 45 to 54 aver age $19,818 in expenditures. The following conclusions are evident:
1. Expenditures generally increase with age and are much higher at older ages. 2. Expenditures incurred at any age depend on whether the individ ual survives or dies, with expenditures for decedents higher than for survivors, especially at older ages. 3. Expenditures for smokers exceed those for neversmokers at every age among both survivors and decedents. 4. To be a smoker is expensive, and to be a smoker and die is most expensive.
Although expenditures for females tend to exceed those for males, the relationships observed for males, in terms of survivors versus decedents, smokers versus neversmokers, generally hold for females also (figure 3).
E x p ected E xpenditures
Applying probabilities of surviving and dying to survivor and decedent expenditures yields age-specific expected medical expenditures (figure 4). These are the discounted expenditures we expect the average individual aged 17 to incur during each age interval for the remainder of his or her life, according to whether the person is a smoker or neversmoker. A 17-year-old deemed to be a smoker is one who is or will become a smoker, probably within five years. Females generally have higher medical ex penditures than males, but the relationship of expenditures to smoking is the same for both. Through age 74, smokers have higher expenditures at each age, but after age 75 neversmokers have higher expenditures.
Here we see the impact of lower mortality rates and longer life expec-
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F I G . 3 . Female medical expenditures during age intervals according to smoking and survival status. tancy of neversmokers. Smokers who do survive to older ages have higher medical care costs (figures 2 and 3). However, because of lower probabilities of survival, so many fewer smokers compared with never smokers live to age 75 or beyond that the average, or expected, expendi ture that will be incurred is less per smoker than per neversmoker. Expected expenditure is the proper conceptual measure for estimating average lifetime expenditures and is the basis for the analysis in the re mainder of this article. The influence of discounting on monetary values far in the future is apparent. Although discounting decreases the present value o f all ex penditures, the impact is greatest on more highly discounted expendi tures in later years. Because future expenditures become less important relative to more current expenditures, the impact of high expenditures by neversmokers relative to smokers in the later years of life on the gap between smokers and neversmokers before age 75 is diminished.
The net effect on smoker versus neversmoker lifetime expenditures of higher expenditures for smokers up to age 75 and lower expenditures after age 75 is shown in figure 5. Figure 5 plots the cumulative excess (smoker minus neversmoker) expenditures that smokers incur from age 17 to the age shown. The cumulative difference reaches a peak at age 75 and declines thereafter. The total of medical expenditures incurred by male and female smokers remains higher than for neversmokers through out their lives; the gap narrows after age 75 but remains positive. The net lifetime excess expenditures for smokers compared with neversmok ers is shown at age 95. Over their lifetimes male smokers average $8,638 more than neversmokers and female smokers average $10,119 more.
T o ta l L ifetim e E xpenditu re
Total expected lifetime medical expenditures from age 17 are higher for smokers than neversmokers and increase with the amount smoked (ta ble 2). Lifetime expenditures for male moderate smokers (fewer than 25 cigarettes a day) for hospital care, physicians' services, and nursing-home care average $32,891 in 1990 dollars, which is $5,615 and 21 percent higher than the $27,276 for neversmokers. Heavy smokers (25 or more (Hatziandreu et al. 1989; Warner 1978) , some moderate smok ers may consume more than 25 cigarettes a day and the least amount consumed by heavy smokers may be more than 25 cigarettes a day. Females use more medical care at most ages and live longer than males, and therefore have higher lifetime expenditures. The amount of smoker excess expenditures is higher for females than males, but the ra tio of smoker to neversmoker expenditures is smaller for females. Excess lifetime expenditures are $6,135 for moderate smokers, $17,564 for heavy smokers, and average $10,119 for all female smokers. Lifetime ex penditures are 14 percent higher for female moderate smokers than nev ersmokers and 41 percent higher for heavy smokers, with average expenditures 24 percent higher for all female smokers.
To show the sensitivity of our results to the discount rate, we have also estimated lifetime expenditures discounted at 5 percent. At higher discount rates dollar amounts are less, but the disparity between smok ers and neversmokers increases. At 5 percent, average smoker lifetime expenditures are 37 percent higher for males and 31 percent higher for females.
The relatively smaller impact of smoking on female expenditures is consistent with lower cigarette smoke exposure among females in the past. Lower exposure results in lower mortality (U.S. Department of Health and Human Services 1989) and lower medical care use (Rice et al. 1986 ) relative to neversmokers among females. Lower relative mor tality and medical care use in turn produce a smaller proportionate in crease in lifetime medical expenditures of smokers compared with neversmokers for females. As female exposure approaches that of males, we can expect lifetime expenditures o f female smokers to increase rela tive to neversmokers.
Excess M edical Care Versus Excess M ortality
Thus far we know smokers use more medical care at all ages when they are alive than neversmokers, whereas neversmokers live longer and use medical care over a greater number of years. The impact of higher medi cal care use while alive outweighs shorter life expectancy and, on balance, male and female smokers have higher lifetime medical expenditures than neversmokers. The ratio of smoker expenditures to neversmoker expenditures in table 3 shows how smoker expenditures exceed never smoker expenditures during each age interval up to age 75, whereas neversmokers incur higher expenditures after age 75.
The separate contributions of excess medical care and excess mortality can be appreciated by comparing lifetime expenditures of smokers with lifetime expenditures o f two hypothetical groups: (a) smokers with med ical care use o f neversmokers (smoker expenditures adjusted for medical care) and (b) smokers with mortality rates of neversmokers (smoker ex penditures adjusted for mortality). Comparing smoker lifetime expendi tures with expenditures adjusted for medical care, we observe the contribution of higher medical care use to smoker expenditures. For males and females, excess expenditures due to higher medical care use are highest in the middle years of the life span and fall off rapidly dur ing the later years. Excess medical care use of smokers increases their lifetime medical expenditures by 43 percent for males and by 29 percent for females.
The impact of higher mortality rates on lifetime medical expenditures is observed from the comparison of smoker expenditures with expendi tures adjusted for mortality. Up to age 65 for males and age 75 for fe- males, smokers have as high or higher expenditures as the hypothesized smoker with neversmoker mortality rates. This can be attributed to the high cost of dying, which, for this period of the life cycle, outweighs the smoker's lower probability of surviving to each age and incurring expen ditures. At older ages, however, the cumulative effect of higher smoker mortality rates has so reduced the probability that a smoker will survive to these ages that expected expenditures are much lower for smokers.
Smoker expenditures decline rapidly with advancing age relative to ex penditures adjusted for smoker excess mortality. The net effect of excess smoker mortality, given by the result for all ages, is to reduce male smoker lifetime expenditures by 5 percent and female smoker lifetime expenditures by 3 percent. Up to age 75, smoker expenditures exceed neversmoker expenditures almost solely because of higher smoker medical care use; excess mortality and the high cost o f dying make a small contribution. After age 75, ex pected smoker expenditures are much less than neversmoker expendi tures. At the older ages excess smoker medical care use makes a positive but greatly reduced contribution to smoker expenditures, and this is outweighed by the reduction in expenditures resulting from the impact at these ages o f the cumulative effect o f excess smoker mortality in prior years. The net effect is higher lifetime expenditures for medical care for smokers.
Population Expenditures
In the preceding sections I examined individuals' medical care expendi tures. These results enable us to assess the aggregate burden imposed by cigarette smoking. Each year, more than one million young persons in the United States start smoking (Pierce et al. 1989) . And each year, ap plying the results in table 2, decisions by young people to take up smoking commit the health care system to extra medical care expendi tures totaling $9.4 billion (discounted at 3 percent), spread out over the lifetimes of each new crop o f smokers.
Medical expenditures expected over the remaining lifetime have been estimated by smoking status and sex for each age group, from 25 to 34 years of age to 85 years and older. Applying these profiles of remaining lifetime expenditures per person to the civilian noninstitutionalized population 25 years of age and older residing in the United States in 1985 gives future expenditures attributed to the baseline population. The baseline population will generate medical expenditures for 65 years, at which time the last surviving members will be at least 90 years old and the process is truncated. In addition to future expenditures attrib uted to the baseline cohort of smokers, we also calculate excess smoker expenditures or the amount by which smoker expenditures exceed ex penditures that would be incurred if smokers had the medical care use and mortality o f neversmokers. From these calculations we derive the re sults that follow.
Sm oking a n d M edical E xpenditures
IO I
The N e x t Five Years Figure 6 shows the aggregate excess medical expenditures, in 1990 dol lars, generated by the baseline population of smokers. In the first five years, excess expenditures attributed to male smokers are $113.5 billion, equal to $2,525 per smoker. Female smokers are estimated to have $73.1 billion o f excess medical expenditures, averaging $2,069 per smoker. Medical expenditures for hospital care, physicians' services, and nursing-home care for the total baseline population (smokers and neversmokers) during these five years is estimated at $1,026.5 billion, $420.5 billion for males and $605.9 billion for females. Thus, excess expendi tures associated with cigarette smoking account for $186.6 billion, 18 percent of medical expenditures required by all persons (smokers and neversmokers) aged 25 and over in the first five years from baseline. The corresponding figures are 27 percent for males and 12 percent for fe males.
Discounting at 5 percent instead o f 3 percent decreases aggregate ex cess expenditures by about 6 percent among males and females, but the proportion o f total expenditures required for smokers' excess medical care does not change with the discount rate. This scenario will continue, more or less uninterrupted, at least in the short term, in the absence of significant changes in important param eters. That is, about one fifth o f medical expenditures for persons aged 25 and over will go to pay for additional medical care required by smok ers. Gradual changes in important parameters over a period of years can have a cumulative, and ultimately significant, impact as well, and such changes are being recorded. In addition to general demographic changes in the population, smoking habits have changed: fewer males take up smoking, although the proportion of neversmokers among females was In addition to changes in the rates at which young people take up smoking and smokers quit, the number of cigarettes smoked and the nature of cigarettes, a host o f other factors could influence the health ef fects of smoking and attendant medical expenditures. These are very difficult to predict and have the potential either to increase or decrease expenditures. Progress in eliminating competing disease and increasing life expectancy would increase the relative risk o f smoking-related mor bidity and mortality. Changes in personal health practices, such as diet and exercise and exposure to chemicals in air, water, and food, may al ter risks associated with smoking to the extent that there are synergistic relations among risks for diseases like cancer, coronary heart disease, and pulmonary disease. Advances in medical therapy may improve survival rates or lessen the severity of the condition and affect medical care ex penditures. Medical treatment has changed significantly over the years and changes will continue into the future. For some conditions consider able change in medical care utilization occurs in a short period of time (Hodgson 1988 ). The cost of treating an illness may increase or decrease as the method of treatment changes (Scitovsky 1967 (Scitovsky , 1985 Scitovsky Sm oRtng a n a m eatcai cxp e n a tiu res i o 3 and McCall 1977). Although methods o f treatment are certain to change, the effect of these changes, coupled with changes in financing mechanisms that also impact on medical care utilization and costs, is uncertain.
The future medical costs of the health effects of smoking depend on many diverse factors including smoking behavior, the incidence or prev alence of smoking-induced diseases, and methods and costs o f treat ment. Projecting the divergence of the future values of many of these parameters from currently observed values, and the net effect of changes in several factors, would be speculative. However, research is planned that will take account of the changing prevalence of smoking in project ing expenditures, and will also assess the impact of decisions to quit smoking on individual and aggregate medical expenditures.
The C urrent C oh ort o f Sm okers
The remainder of figure 6 shows, in ten-year intervals and cumulatively, projected aggregate excess medical expenditures attributed to the cur rent cohort o f smokers 25 years of age and older over the remainder of their lifetimes. For the first 25 years for females and 35 years for males, the average smoker in the cohort is expected to incur medical expendi tures exceeding what he or she would incur as neversmokers. As a result, the cumulative total rises steadily, especially for males. In subsequent years, as the cohort ages, the shorter life expectancy of smokers relative to neversmokers exerts a dominant influence, excess expenditures turn negative, and the cumulative excess declines.
For the civilian noninstitutionalized population of cigarette smokers in 1985, expected excess expenditures over their remaining lifetimes for hospital care, physicians' services, and nursing-home care total $501 bil lion in 1990 dollars, $355 billion for males and $146 billion for females. This is an average of $7,888 per male smoker and $4,143 per female smoker. These are averages for smokers of all ages; the remaining life time excess is higher for the younger smokers. Discounting at 5 percent instead of 3 percent reduces total expected excess expenditures by 5.6 percent, from $500.9 billion to $473.0 billion.
Source o f Funds for Health Care
Health care expenditures in the United States are funded by a variety of sources. Annually, private funding accounts for 60 percent of total per sonal health care expenditures, consisting mostly o f payments from pri vate health insurance plans and directly from patients, with a small amount from philanthropy and industry. Public payments through Medicare, Medicaid, and other government programs, including the Veterans' Administration, Department of Defense, Indian Health Ser vice, worker's compensation, and maternal and child health, finance 40 percent of personal health care (Letsch, Levit, and Waldo 1988) . The distribution o f health expenditures among funding sources varies mark edly by patient age. Private health insurance and direct payments by consumers of health care account for almost three-fourths of expendi tures for persons under 65 years o f age, whereas public funds, especially Medicare, contribute almost two-thirds of the health expenditures of the elderly (Waldo et al. 1989) .
Given the greater use of health care and higher lifetime medical care expenditures by smokers, albeit shorter life expectancy, how does the burden o f financing smokers' excess medical care fall upon the various funding sources? Is the burden evenly distributed among sources, or do one or more sources bear inordinate shares? Does the burden fall more heavily on either the public or private sector? In addressing this issue, payments from consumers directly out of pocket, other private sources (almost entirely from private health insurance), Medicare, and Medicaid are analyzed. These sources account for 90 percent of all personal health care expenditures (Letsch et al. 1988 ). The remaining 10 percent of ex penditures is paid by a variety of sources for health conditions not gen erally related to smoking. These include workers' compensation medical payments for work-related injuries and illnesses; Veterans Administra tion medical expenditures, which are heavily weighted by medical care for mental conditions; Department o f Defense medical expenditures, over 90 percent of which are for younger persons; maternal and child health and school health programs. Table 4 shows male smokers' lifetime medical expenditures according to smoking status and sources o f funds. As expected because o f their shorter life expectancy, a larger share o f smokers' medical care is paid for by private health insurance (50 percent versus 44 percent), the predomi nant payer for persons under 65 years o f age, whereas 25 percent of neversmokers' medical care compared with 21 percent for smokers is funded by Medicare, the most important source of funds for the elderly. Outof-pocket payments are a slightly larger proportion of neversmokers' medical expenditures, accounting for 21 percent of the total, and Med icaid pays 10 percent of expenditures for both smokers and neversmokers. The distribution of expenditures by source of funds varies hardly at all between heavy smokers and moderate smokers. Smokers' excess medical care is largely financed by private health in surance; 70 percent of excess payments is by private insurance. On aver age, lifetime medical payments per person by private insurance are 51 percent higher for male smokers than neversmokers (36 percent higher for moderate and 70 percent higher for heavy smokers). Heavy smokers also require larger lifetime medical payments from Medicare and Medic aid and pay more out of pocket than neversmokers. Moderate smokers also benefit substantially more from Medicaid and pay more out of pocket than neversmokers, but receive only slightly more from Medi care. Shorter life expectancy among smokers does not save the Medicare program money. Although neversmokers live longer, moderate and heavy smokers require substantially greater expenditures for medical care than neversmokers at ages 65 to 74, largely funded by Medicare. Medicare expenditures are 21 percent higher for heavy smokers and 1 percent higher for moderate smokers than for neversmokers, and on av erage 8 percent higher for smokers. (Of course, the average for all smok ers depends on the relative numbers of moderate and heavy smokers in the population.)
E xpenditu res over th e S m o k er' s L ifetim e
Females use more medical care, incur higher expenditures, and gen erally receive more funds from each source than males (table 5). The distribution o f female medical expenditures by source of funds is very much like that of males with respect to out-of-pocket and private pay ments, whereas Medicare pays relatively less for females and Medicaid pays relatively more. Female smokers' excess medical care is also largely financed by private health insurance (72 percent of the excess, on aver age); and private health insurance payments range from 23 percent higher for moderate smokers to 64 percent higher for heavy smokers than neversmokers. Female smokers also pay more out of pocket and re ceive more from Medicaid, but Medicare pays a little less for female smokers than neversmokers.
If expenditures are discounted at 5 percent instead of 3 percent, the share of lifetime expenditures paid by private insurance increases and that paid by Medicare decreases. Because these changes are somewhat larger for neversmokers, there is a resulting decrease in the proportion of excess smoker expenditures paid by private insurance, from 70 to 65 percent among males and 72 to 67 percent among females. The contri butions of out-of-pocket payments and Medicare to excess smoker medi cal expenditures increase modestly as the discount rate increases. Wright (1986) investigated the net effect on Medicare's hospital in surance fund o f the decision to quit smoking at age 45 by a male light smoker. Although the issues that Wright and I address are quite differ-S m o kin g a n a M eatcal tx p e n a itu r e s io 7 ent, it is important to comment on Wright's study lest the conclusions of the two analyses appear to be contradictory. Wright asks the following question: for quitters, who live longer, how do additional contributions into the hospital insurance fund compare with additional reimburse ments for Medicare-covered medical services? On the other hand, our study considers only Medicare reimbursements and compares payments to smokers with payments to neversmokers. Within Wright's frame work, an analysis more closely related to ours would be to ascertain whether Medicare reimbursements to quitters are higher or lower than reimbursements to nonquitters. Wright finds that for male light smokers who quit at age 45, reim bursements from the hospital insurance fund during additional years of life exceed payments into the fund by $934 to $1,495 (in 1980 dollars discounted at 3 percent) depending on alternative assumptions about the investment return on contributions. However, the added Medicare reimbursements for quitters are overstated for two reasons. First, these are based upon average annual reimbursement per enrollee, which is a weighted average of reimbursements to smokers and nonsmokers. It is expected that average annual reimbursement would be lower for nonsmokers, who not only live longer because they are more healthy, but also use less medical care per year. Second, quitters can be expected to enjoy better health and require less medical care not only in the extra years added to their life span, but also in the years between quitting at age 45 and the expected age of death for smokers. Wright does not take into account the reduced Medicare payments in these years and credit them against payments during the extra years of life. Correcting for these two sources of overstatement in Wright's estimate of additional Medi care reimbursements to quitters would substantially reduce the amount by which additional reimbursements exceed contributions to the insur ance fund and quite possibly turn a net expense into a net gain.
P op u la tio n E xpenditures
In the first five years from baseline, excess use of medical care by smok ers 25 years o f age and older in 1985 costs $186.6 billion in 1990 dollars (figure 6 and table 6). More than half o f this, $100.9 billion, is paid by private insurance, while Medicare pays 16 percent ($29.9 billion), Med icaid pays 12 percent ($21.7 billion), and smokers contribute 18 percent ($34.1 billion) directly out of pocket. Male smokers were estimated to generate excess medical expenditures of $113.5 billion in the first five years from baseline. Female smokers have excess medical expenditures totaling $73.1 billion, with somewhat larger proportions than males paid out of pocket, by private insurance, and by Medicaid, and relatively less by Medicare. The five-year profile shows the short-run experience of the health sector in financing smokers' health care. This continues as long as a steady or near steady state obtains. All sources o f funds, public and private, share in the burden o f financing smokers' excess medical care, but the predominant payer is private health insurance. The current population has certain smoking habits, including, for ex ample, amount smoked and rates of quitting at various ages. If these patterns were to continue into the future, the net financial impact on medical care expenditures by the baseline cohort of smokers would be the excess expenditures after 65 years shown in table 6. Total excess ex penditures over the remaining lifetime o f the baseline cohort o f smokers are $500.9 billion, including $354.6 billion for males. For females the long-run excess is much less, $146.3 billion, one reason being that there are many fewer female smokers.
As during the first five years, all payment sources contribute to the excess medical care required by smokers in the long run, although the share paid by private insurance is higher while the proportions paid by other sources are lower. O f the total excess medical expenditures of $501 billion required by all smokers over the lifetime of the cohort, 79 per cent is paid by private insurance, 11 percent by Medicare, and 5 percent each by smokers out of pocket and Medicaid. The shift in the burden of funding excess medical expenditures to private insurance is greater for females, with the additional funds paid by private insurance being 97 percent of the net excess required. Medicare provides a small but signifi cant portion while out-of-pocket and Medicaid expenditures are less for female smokers than neversmokers.
Increasing the discount rate from 3 percent to 5 percent decreases population excess medical expenditures by 6.5 percent to $174.5 billion after five years from baseline and by 5.6 percent to $473.0 billion after 65 years from baseline. The distribution of excess expenditures by source of funds does not change with the discount rate in the first five years. Because of the greater impact of discounting on expenditures for never smokers who live longer, however, after 65 years there is a shift in pay ment for smokers' excess medical care from private insurance to the other sources of funds. Private insurance payments decrease from 79 percent of the total to 67 percent, while out-of-pocket payments in crease to 11 percent, Medicare's share increases to 14 percent, and Med icaid pays 8 percent. The change is greatest among females whose expenditures are most affected by discounting because of their longer life expectancy. At a 5 percent discount rate, the distribution of excess expenditures for females is 75 percent private insurance, 8 percent outof-pocket, 11 percent Medicare, and 7 percent Medicaid.
Summary and Conclusion
The cumulative impact o f excess medical care required by smokers at all ages while alive outweighs shorter life expectancy, and smokers incur higher expenditures for medical care over their lifetimes than never smokers. This accords with the findings by Manning et al. (1989) of pos itive lifetime medical care costs per pack of cigarettes, but disagrees with the results found by Leu and Schaub (1983, 1985) for Swiss males. The contradictory conclusions of the analyses are undoubtedly due to a large difference in the amount of medical care used by smokers relative to neversmokers in the United States and Swiss data. Excess expenditures increase with the amount smoked among males and females so that life time medical costs of male heavy smokers are 47 percent higher than for neversmokers when discounted at 3 percent. Each year more than one million young people start to smoke and add an extra $9 to $10 billion (in 1990 dollars discounted at 3 percent) to the nation's health care bill over their lifetimes.
Given the smoking behavior, medical care utilization and costs of care, and population size embedded in the data used in this analysis, I have concluded that in the first five years from baseline the population of smokers aged 25 and over incurs excess medical expenditures totaling $187 billion, which is $2,324 per smoker. The excess cost of medical care associated with cigarette smoking is 18 percent of expenditures for hospital care, physicians' services, and nursing-home care required by all persons (smokers and neversmokers) aged 25 and over. In the absence of large and rapid changes in the values of the underlying parameters, $187 billion, 18 percent of medical expenditures, can be taken as the premium currently being paid every five years to provide medical care for the excess disease suffered by smokers.
Even without the addition of any new smokers, the present value of the bill that will be incurred for excess medical care required by the cur rent population of smokers over their remaining lifetimes is high. The civilian noninstitutionalized population of cigarette smokers in 1985 who are age 25 and older is expected to incur over its remaining lifetime ex cess medical expenditures of $501 billion, or $6,239 per smoker. It is possible that future changes beyond recent historical trends in the habits of those who currently smoke, such as reductions in the amount smoked, higher rates o f quitting, whether occurring fortuitously or brought about by design, may result in lower costs of smoking than estimated. Such an analysis is beyond the scope of this study.
A smoker's lifetime excess medical care is largely financed by private health insurance, with more than 70 percent of the excess paid by this source. But each funding source helps pay for the extra medical care for smokers, except for Medicare's contribution to female expenditures. Medicare pays about 4 percent less for female smokers than neversmok ers when expenditures are discounted at 3 percent.
For the population of smokers in 1985, more than half of the $187 billion in excess expenditures in the next five years ($101 billion) is paid by private insurance. All sources of funds share in the burden, however. In addition to private insurance, 18 percent ($34 billion) is paid out of pocket, 16 percent ($30 billion) by Medicare, and 12 percent ($22 bil lion) by Medicaid. In the long run, over the remaining lifetime of this cohort o f smokers excess medical care costs $501 billion, with 79 per cent, or $395 billion, paid by private insurance and lesser but significant amounts funded by Medicare (11 percent or $54 billion), Medicaid (5 percent or $25 billion), and out of pocket (slightly more than 5 percent or $27 billion).
Our analysis employs a 3 percent discount rate, supplemented with brief descriptions of the impact on key results o f discounting at 5 per cent. A 3 percent rate is at the low end of rates observed in the litera ture and rates above 5 percent give too little weight to expenditures far in the future. The present value of expenditures decreases as the dis count rate increases. More important, however, is the impact on the re lationships between smoker and neversmoker medical expenditures. Discounting at 3 percent is conservative in that the ratio of smoker to neversmoker lifetime expenditures increases with the discount rate. Ag gregate excess expenditures for the population o f smokers are less at the higher discount rate, but the decrease is only around 6 percent. Most sensitive to the discount rate is the contribution of various sources of payment to excess smoker medical expenditures. At higher discount rates less of the excess is paid by private insurance and more by other sources of funds. Yet even this difference is quantitative rather than qualitative. Private insurance remains the primary payer, with Medicare, Medicaid, and out-of-pocket payments providing smaller but important contributions.
This study has not controlled for certain factors such as alcohol con sumption, other lifestyle attributes, income, and education. To the ex tent that there is a correlation between these and smoking resulting in increased medical care use among smokers, not all of the observed dif ferences in lifetime expenditures between smokers and neversmokers are due to smoking. Nevertheless, the analysis by Manning et al. (1989) in dicates that 87 percent o f the differences would remain after controlling for important confounding variables.
Adjusting the key results to reflect only 87 percent o f the observed differences between smoker and neversmoker lifetime medical expendi tures produces the following for a 3 percent discount rate. Expected life time medical expenditures o f the average smoker exceed those of the average neversmoker by 28 percent ($7,515) for males and 21 percent ($8,804) for females. Each year, decisions by more than one million young people to take up smoking commit the health care system to $8.2 billion in extra medical expenditures over their lifetimes. At current rates, the population of smokers 25 years and older incurs $162 billion in excess medical expenditures every five years. The population of smok ers at least 25 years o f age in 1985 is expected to incur excess medical ex penditures o f $436 billion over their remaining lifetimes, $6,863 per male smoker and $3,604 per female smoker.
It is reasonable to conclude that the results in our study reveal the qualitative nature o f the impact of smoking on medical care expendi tures, both for individuals and in the aggregate, and are reasonably close quantitatively. Smoking both raises medical care expenditures over the smoker's lifetime, with costs rising the more one smokes, and in creases society's expenditures for medical care as well as the burden on public and private sources of funds. Reductions in the number of per sons who ever smoke and the amounts smoked will benefit all payers of medical care, decreasing the financial obligations of both public and private sources o f funding.
This study estimates the lifetime expenditures of eversmokers and neversmokers, thus assessing the impact of becoming a smoker. It does not assess the impact o f quitting smoking. Former smokers can be ex pected to consist of two groups: those who quit while in apparent good health to avoid future consequences of smoking, and those who quit to prevent or reduce further exacerbation o f an existing smoking-related health problem. Health care use and mortality of the former group would likely decline over a period of time from at or below the levels of all current smokers and approach levels experienced by neversmokers. Health care use and mortality of the latter group could be expected to be higher than levels observed among all current smokers, possibly for a few years, and also decline with time to levels between current and nev ersmokers.
The impact of quitting on an individual smoker's lifetime medical expenditures will depend on the type of former smoker (whether he or she quits when in good or failing health), amount smoked, number of years of smoking, and age at quitting. From the time of quitting, we would expect annual medical expenditures of former smokers to fall to a level between expenditures incurred by current and neversmokers, but to continue for more years than expenditures for current smokers, possi bly as long as neversmokers. The key factor may be age at quitting. Quitting at earlier ages not only increases the number of years of re duced medical expenditures, but may also result in a lower level of an nual expenditures and further increase life expectancy if, by quitting n 4 earlier, fewer deleterious health effects result from prior tobacco expo sure. The amount of savings depends on the tradeoff between the sepa rate impacts on lifetime expenditures of lower annual medical costs after quitting and added years of expenditures due to a longer lifetime. The aggregate reduction in expenditures for the population will depend on how many smokers quit, at what ages, and in what state of health. The effect of quitting on lifetime medical expenditures of smokers is a com plex issue to which we hope to contribute some analysis in a future pub lication.
Lifetime expenditures from age 17 are given by: #=17-34 where Eat = expenditures during age interval t if the individual survives through t Eat = probability of surviving through age interval t
• Edt -expenditures during age interval / if the individual dies in t Pdt = probability of dying during age interval t t = age 17-34, 35-44, 45-54, 55-64, 65-74, 75-84, 85 and over i = discount rate
The components o f Et are described below. NHIS in 1974 and shows that during the decade ageadjusted relative risks o f hospital care and physician services for smokers increased except for a very small decrease among females in the relative risk of hospital use. The data used in this study thus somewhat underes timate more recent use o f medical care by smokers relative to nonsmok ers and, consequently, conservatively estimate the amount by which lifetime medical expenditures of smokers exceed those of persons who never smoked.
Survivor E xpenditu res
NHIS hospital days and physician visits per capita in a year are biased measures of use by survivors in our model; that is, persons who live to the end of an age interval. The bias derives from the influence o f dece dents in subsequent years on per capita use observed in NHIS in a base year. Decedents are known to have higher than average medical care use several years prior to their deaths. Consequently, per capita use in the NHIS is the overall per capita use of two groups: (1) long-term survi vors-those who will be alive at least several years after the base period, and (2) short-term survivors -those who will die within a few years fol lowing the base period. Thus, in the base year, observed per capita use in NHIS is likely to be higher than per capita use of long-term survivors and lower than that of short-term survivors. Per capita use by long-term survivors is the appropriate measure of use by survivors in the model in our analysis.
Even if the factor by which base period utilization exceeds long-term survivor utilization is the same for smokers and neversmokers, the dif ference in use between long-term surviving smokers and neversmokers is overstated if measured by base period per capita rates. Furthermore, be cause smokers have higher mortality rates than neversmokers, a larger proportion of smokers in the base year are short-term survivors and a smaller proportion are long-term survivors than among neversmokers. The impact of short-term survivors on per capita medical care use in the base period is greater among smokers than neversmokers. This results in additional overstatement of long-term survivor smoker use compared with neversmoker use measured by base period per capita rates. The overstatement increases with age, as do mortality rates, and short-term survivors become a larger proportion o f the base year population.
To estimate more accurately expenditures for survivors, decedents, smokers, and neversmokers over their lifetimes, long-term survivor hos pital and physician use is estimated from NHIS base period utilization. This is accomplished as follows: Cohen, Tell, and Wallack (1986) .
D e ce d en t E xpenditu res E jt -H t CHtK Ht + D t Cot KDt + N H jt
Medical expenditures for hospital care and physicians' services for de cedents are estimated from expenditures for survivors by means of the relationship o f expenditures of decedents relative to survivors observed in several populations. Thus, average annual hospital and physician ex penditures for survivors are multiplied by K Ht and K Dt, respectively, to obtain hospital and physician expenditures for decedents.
K fit = the multiple by which hospital expenditures for decedents in the period t exceed average annual hospital expenditures for survivors. For decedents less than 65 years of age, K Hl is derived from hospital care expenditures for decedents and survivors in the year of death in NMCUES and hospital care utilization in the four years prior to death in a probability sample of 60,000 Canadians reported by Roos, Montgomery, and Roos (1987) .
For decedents 65 years of age and older, K Ht is derived en tirely from expenditures of decedents relative to survivors in the population o f Medicare beneficiaries. The Medicare data are described in Lubitz and Prihoda (1984) and Riley and Lubitz ( 1986) . K Dt = the multiple by which physician expenditures for decedents in the period t exceed average annual physician expenditures for survivors. K Dt is derived from the same data sources and meth ods as is KutNursing-home expenditures, if the individual dies at age t, are esti mated by N H jt -1.5(.25 Lat + .7 5 L jt )C NHt Wjt La, = average length of stay for live discharges, as described above.
L jt = average length of stay for dead discharges, also from the NNHS and inflated by 30 percent. The average length of stay for decedents is a weighted average of the lengths o f stay of live and dead discharges, with the weights reflecting the assumption that 75 percent of those with a long-term stay die in the institution (Vicente, Wiley, and Carrington 1979) . CNHt = average daily charge to nursing-home residents in 1990 dol lars by age and sex from the NNHS.
Wdt -percent of the population dying in age t who had a nursinghome stay in the period by age, sex, and smoking status from NHEFS. -34, 35-44, 45-54, 55-64, 65-74, 75-84, 85 and over.
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For example, £>,45-54 = ( 1 ~ £ l 7 -3 4 ) ( l -£ 3 5 -4 4 ) ( l -£ 45-54) P j , 45-54 = .£ 4 5 -5 4 ( 1 -£ l 7 -3 4 ) ( l -£ 3 5 - 4 4 ) p " = the probability of dying in the »th age interval for persons alive at the beginning o f the age interval by sex and amount smoked. The p ns are derived from death rates in the American Cancer Society's (ACS) Cancer Prevention Study II (CPS II). The p " s are scaled to 1985 U.S. values for all males and females following the methodology em ployed by Mattson, Pollack, and Cullen (1987) .
CPS II is a long-term prospective study. In 1982, more than 77,000 ACS volunteers enrolled 509,000 men and 677,000 women, who pro vided information on their lifestyles, exposure to certain environmental conditions, and history o f disease. , it was de termined which enrollees had died in the two preceding years and death certificates were obtained. Although subjects come from all 50 states, the District o f Columbia, and Puerto Rico, the sample is not a probabil ity sample o f the U.S. population. Minority groups are underrepre sented, institutionalized persons are excluded, and sample persons are more highly educated (Stellman and Garfinkel 1986) .
CPS II is more representative o f middle-class white Americans and the enrollees' mortality rates are lower than those of the total U.S. pop ulation (U.S. Department o f Health and Human Services 1989). Longer life expectancy among CPS II enrollees would produce some overstate ment of lifetime medical expenditures for the U.S. population. The im pact on excess smoker expenditures is not clear. It depends on whether, and by how much, underrepresentation of minorities differs among smokers and neversmokers, and on certain other characteristics that pro duce different smoker versus neversmoker mortality among minority and nonminority populations. For example, higher proportions of blacks currendy smoke, but a higher proportion o f whites are former smokers, whereas Hispanics have the highest proportion o f neversmokers and the lowest proportion o f current smokers (Schoenborn and Boyd 1989) . Whites smoke more cigarettes per day (National Center for Health Statistics 1988), whereas black smokers prefer cigarette brands that are high in tar and nicotine and are mentholated (Novotny et al. 1988 ). The net effect of these competing factors on the relative mortal ity o f smokers and neversmokers is uncertain.
The higher educational level of the CPS II sample is due at least in part to underrepresentation o f minorities. A line o f reasoning similar to that in the preceding paragraph applies to whether educational differ ences between the CPS II sample and the U.S. population not caused by minority underrepresentation impact on excess smoker expenditures.
The potential for CPS II to provide reasonable generalizations to the U.S. population is shown by Stellman and Garfinkel (1986) . They find that adjusting CPS II data for the educational distribution of the United States by ten-year age groups produces only small changes in the agespecific distributions o f smoking habits among men and women. Fur ther encouragement for the use o f CPS II is given by the surgeon general, who reports that estimated relative risks for cigarette-related diseases do not change much in response to statistically controlling for confounding and stratifying variables (U.S. Department of Health and Human Services 1989). Even with its limitations, CPS II is the best available data source for this analysis.
P opu lation E xpenditu res
Expected medical expenditures per individual over the remaining life time are estimated for each smoking status, sex, and age group. Each profile o f expected expenditures is then multiplied by the corresponding number of persons in the group as estimated by the NHIS for 1985. This produces aggregate expected expenditures for each cohort by age and years from baseline.
Source o f Funds
The Health Care Financing Administration (HCFA) annually estimates national health expenditures by source o f funds for each type of medical care (Letsch, Levit, and Waldo 1988) . From time to time, national health expenditures are disaggregated by age (Waldo and Lazenby 1984; Waldo et al. 1989) , usually into three age groups: under 19 years, 19 to 64 years, and 65 years of age or over. The following steps were taken to allocate lifetime medical expenditures o f each smoking status group (male neversmokers, for example) according to payment sources.
